Work

Plasma biomarkers, brain amyloid pathology, and cortical thickness in a racially diverse community cohort: the Human Connectome Project

Year: 2025

Type: article

Abstract: BACKGROUND: Plasma biomarkers are critical for early detection and treatment of Alzheimer's disease (AD). We assessed plasma biomarker association and classification capacity against neuroimaging measures. METHOD: In the racially diverse Human Connectome Project (HCP; n = 218, 15% Aβ-PET-positive) Aβ-PET and cortical thickness (neurodegeneration) were related to plasma biomarkers (p-tau181, p-tau217 [Janssen and ALZpath], p-tau231, GFAP, NfL, Aβ42/Aβ40). RESULT: Plasma p-tau217 accurately identified abnormal Aβ-PET (: AUC=0.9145, 95% CI=[0.8367, 0.9923]) followed by GFAP and Aβ42/40 ratio (GFAP (AUC=0.8529, 95% CI = [0.7485, 0.9573], Aβ42/40 (AUC = 0.7962, 95% CI = [0.6581, 0.9346]). All biomarkers performed poorly to identify cortical thickness, but were increased according to combined Aβ-PET-neurodegeneration profiles. Correlations of p-tau217, p-tau181, and Aβ42/40 with Aβ-PET were stronger in self-identified non-Hispanic Whites vs. Black/African Americans. CONCLUSION: Plasma biomarkers identify brain Aβ pathology in the community. However, consideration of potential racial/ethnic differences in brain-to-blood biomarker correlations should be critically examined and addressed to enable widespread cross-population applications.

Source: Alzheimer s & Dementia

DOI: 10.1002/alz70856_107562

Author: Shayna Brodman

Institution: University of Pittsburgh Medical Center

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,200